Está usando un navegador no compatible.
Es posible que algunas características de este sitio no funcionen correctamente. Para tener una experiencia de usuario óptima, vea este sitio en Chrome, Firefox, Safari o Edge.

Congresos

Materiales de congresos

Tenga acceso a resúmenes, pósteres y presentaciones de los siguientes congresos

Enero 2025

ASCO-GI (Sociedad Estadounidense de Oncología Clínica - Simposio de Cánceres Gastrointestinales)

ASCO-GI (Sociedad Estadounidense de Oncología Clínica - Simposio de Cánceres Gastrointestinales)

January 2025 (San Francisco, CA)

Pósteres

Alternative dosing regimens of tislelizumab proposed using modeling and simulation First-in-human, phase 1a, dose escalation study of BGB-B167, a CEA x 4-1BB bispecific antibody, as monotherapy or combined with tislelizumab (anti-PD-1), in patients with selected advanced or metastatic solid tumors First-line (1L) tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 Japanese subgroup analysis with longer follow-up Impact of tislelizumab + chemotherapy versus placebo + chemotherapy on patient-reported symptoms and disease progression by programmed death-ligand 1 expression in gastroesophageal adenocarcinoma: a post hoc analysis of the RATIONALE-305 trial Impact of tislelizumab + chemotherapy versus placebo + chemotherapy on patient-reported symptoms and overall survival (OS) by programmed death-ligand 1 (PD-L1) expression in advanced or metastatic esophageal squamous cell carcinoma (ESCC): A post hoc analysis of the RATIONALE-306 trial Response characteristics of tislelizumab (TIS) plus chemotherapy (chemo) in first-line (1L) treatment of locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): a post hoc analysis of RATIONALE-306 Tislelizumab (TIS) + chemotherapy (chemo) vs placebo (PBO) + chemo as first-line (1L) treatment in gastric/gastroesophageal junction adenocarcinoma (GC/GEJC) patients with/without peritoneal or liver metastases: a post hoc analysis of RATIONALE-305 study

Resúmenes

Alternative dosing regimens of tislelizumab proposed using modeling and simulation First-in-human, phase 1a, dose escalation study of BGB-B167, a CEA x 4-1BB bispecific antibody, as monotherapy or combined with tislelizumab (anti-PD-1), in patients with selected advanced or metastatic solid tumors First-line (1L) tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 Japanese subgroup analysis with longer follow-up Impact of tislelizumab + chemotherapy versus placebo + chemotherapy on patient-reported symptoms and disease progression by programmed death-ligand 1 expression in gastroesophageal adenocarcinoma: a post hoc analysis of the RATIONALE-305 trial Impact of tislelizumab + chemotherapy versus placebo + chemotherapy on patient-reported symptoms and overall survival (OS) by programmed death-ligand 1 (PD-L1) expression in advanced or metastatic esophageal squamous cell carcinoma (ESCC): A post hoc analysis of the RATIONALE-306 trial Response characteristics of tislelizumab (TIS) plus chemotherapy (chemo) in first- line (1L) treatment of locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): a post hoc analysis of RATIONALE-306 Tislelizumab (TIS) + chemotherapy (chemo) vs placebo (PBO) + chemo as first-line (1L) treatment in gastric/gastroesophageal junction adenocarcinoma (GC/GEJC) patients with/without peritoneal or liver metastases: a post hoc analysis of RATIONALE-305 study.
Diciembre 2024

SABCS (Simposio sobre Cáncer de Mama de San Antonio)

SABCS (Simposio sobre Cáncer de Mama de San Antonio)

Diciembre de 2024 (San Antonio, Texas)
Diciembre 2024

ASH (Sociedad Estadounidense de Hematología)

ASH (Sociedad Estadounidense de Hematología)

Diciembre de 2024 (San Diego, California, EE. UU.)

Pósteres

BGB-11417-203, an ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenstrom macroglobulinemia CELESTIAL-TNCLL: an ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naive CLL Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: growth modulation index analysis from ROSEWOOD study Deep and sustained responses in patients with CLL treated with zanubrutinib or zanubrutinib + obinutuzumab in phase 1/2 AU-003 and phase 1b GA-101 studies: a report from the zanubrutinib extension study Evaluating reasons for differences in real-world clinical outcomes among patients with relapsed/refractory mantle cell lymphoma on covalent BTK inhibitors Impact of novel therapies on real-world clinical outcomes of patients with relapsed/refractory mantle cell lymphoma by race/ethnicity and TP53 mutation status Long-term clinical outcomes in patients with Waldenstrom macroglobulinemia who received zanubrutinib in the phase 3 ASPEN study: a report from the zanubrutinib extension study Long-term impact of dose interruptions of Bruton tyrosine kinase inhibitors on change in IgM levels and clinical outcomes in Waldenström macroglobulinemia Multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in treatment-naive chronic lymphocytic leukemia: 5-year follow up, retreatment outcomes, and impact of MRD kinetics (ΔMRD400) Patient medication preferences in follicular lymphoma in the United States: a discrete choice experiment Preliminary efficacy and safety of the Bruton tyrosine kinsae degrader BGB-16673 in patients with relapsed or refractory indolent NHL: results from the phase 1 CaDAnCe-101 study Prospective patient preference study for Bruton tyrosine kinase inhibitor treatment attributes and factors affecting patient shared decision-making in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States Real-world Bruton tyrosine kinase inhibitor utilization and clinical outcomes among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma Sustained superiority of zanubrutinib vs bendamustine + rituximab in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: 5-year follow-up of cohort 1 from the SEQUOIA study Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies iPSC-derived CAR-γδT with novel combinatorial KO demonstrated extended longevity and profound anti-tumor efficacy without cytokine support in preclinical studies

Resúmenes

BGB-11417-203, an ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia BGB-16673, a selective BTK degrader, exhibits deeper inhibition of cancer cell signaling pathways and better efficacy in MCL models CELESTIAL-TNCLL: an ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naive CLL Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: growth modulation index analysis from ROSEWOOD study Deep and sustained responses in patients with CLL treated with zanubrutinib or zanubrutinib + obinutuzumab in phase 1/2 AU-003 and phase 1b GA-101 studies: a report from the zanubrutinib extension study Discovery of the unique GMP-Grade iPSC clones that give rise to functional, high purity, matured CD8 αβT or γδT with exponential expansion capacity Evaluating reasons for differences in real-world (RW) clinical outcomes among patients with relapsed/refractory mantle cell lymphoma (R/R MCL) on covalent BTK inhibitors (cBTKis) Final analysis of a phase 1 study of zanubrutinib plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma Impact of novel therapies (NTs) on real-world (RW) clinical outcomes of patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) by race/ethnicity and TP53 mutation status Long-term clinical outcomes in patients with Waldenström macroglobulinemia (WM) who received zanubrutinib in the phase 3 ASPEN study: a report from the zanubrutinib extension study Long-term impact of dose interruptions (DIs) of Bruton tyrosine kinase inhibitors (BTKis) on change in IgM levels and clinical outcomes in Waldenström macroglobulinemia (WM) Multicenter Phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in treatment-naïve chronic lymphocytic leukemia: 5-year follow up, retreatment outcomes, and impact of MRD kinetics (ΔMRD400) Patient medication preferences in follicular lymphoma (FL) in the United States (USA): a discrete choice experiment (DCE) Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory (R/R) indolent NHL: results from the phase 1 CaDAnCe-101 study Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory Waldenström macroglobulinemia: results from the phase 1 CaDAnCe-101 study Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: results from the phase 1 CaDAnCe-101 study Prospective patient preference study for Bruton tyrosine kinase inhibitor (BTKi) treatment attributes and factors affecting patient shared decision-making chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in the United States (USA) Real-world Bruton tyrosine kinase inhibitor (BTKi) utilization and clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) Sonrotoclax and zanubrutinib as frontline treatment for CLL demonstrates high MRD clearance rates with good tolerability: data from an ongoing phase 1/1b study BGB-11417-101 Sustained superiority of zanubrutinib vs bendamustine + rituximab in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL): 5-year follow-up of cohort 1 from the SEQUOIA study Treatment with zanubrutinib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were previously treated with another Bruton tyrosine kinase inhibitor in a US community oncology setting Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies iPSC-derived CAR-γδT with SOCS1/CISH/BIM/FAS combinatorial KO demonstrated extended longevity and profound anti-tumor efficacy without cytokine support in preclinical studies
Diciembre 2024

ESMO-Asia (Sociedad Europea de Oncología Médica - Asia)

ESMO-Asia (Sociedad Europea de Oncología Médica - Asia)

Diciembre de 2024 (Singapur)
Noviembre 2024

ISPOR-EU (Sociedad Internacional de Farmacoeconomía e Investigación de Resultados)

ISPOR-EU (Sociedad Internacional de Farmacoeconomía e Investigación de Resultados)

Noviembre de 2024 (Barcelona, España)
Noviembre 2024

AIOM (Asociación Italiana de Oncología Médica)

AIOM (Asociación Italiana de Oncología Médica)

Noviembre de 2024 (Roma, Italia)
Noviembre 2024

SPH (Sociedad Portuguesa de Hematología)

Noviembre 2024

SITC (Sociedad de Inmunoterapia contra el Cáncer)

Octubre 2024

BLOOD (Asamblea Científica Anual de Sangre)

BLOOD (Asamblea Científica Anual de Sangre)

Octubre de 2024 (Brisbane, Australia)
Octubre 2024

American Society of Nephrology Kidney Week (ASN Kidney Week)

Octubre 2024

SIOP (Sociedad Internacional de Oncología Pediátrica)

Octubre 2024

IWWM (Taller Internacional sobre la Macroglobulinemia de Waldenström)

IWWM (Taller Internacional sobre la Macroglobulinemia de Waldenström)

Octubre de 2024 (Praga, República Checa)
Octubre 2024

DGHO (Sociedades Alemana, Austríaca y Suiza de Hematología y Oncología)

DGHO (Sociedades Alemana, Austríaca y Suiza de Hematología y Oncología)

Octubre de 2024 (Basilea, Suiza)

Resúmenes

2 years of zanubrutinib in Germany: a retrospective cohort study Combination of zanubrutinib (zanu) + venetoclax (ven) for treatment-naive (TN) CLL/SLL with del(17p) and/or TP53: preliminary results from SEQUOIA arm D Combination treatment (tx) with novel BCL2 inhibitor sonrotoclax (sonro; BGB-11417) and zanubrutinib (zanu) induces high rate of complete remission in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): minimum 3-year survival follow-up Outcomes ≥1 year after transitioning from treatment with ibrutinib (ibru) in the ASPEN study to zanubrutinib (zanu) Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) CLL/SLL: results from the phase 1 BGB-16673-101 study Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) indolent NHL: results from the phase 1 BGB-16673-101 study Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 Inhibitor, in treatment-naive (TN) patients with acute myeloid leukemia (AML) Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in patients (pts) with relapsed/refractory (R/R) acute myeloid leukemia (AML) Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax (sonro; BGB-11417) in combination with zanubrutinib (zanu) for relapsed/refractory (R/R) CLL/SLL show deep and durable responses Safety and efficacy results of a phase 1 study of the novel BCL2 inhibitor sonrotoclax (sonro; BGB-11417) for relapsed/refractory (R/R) Waldenström macroglobulinemia (WM) Sonrotoclax (sonro; BGB-11417) + dexamethasone (dex) is tolerable and demonstrates antimyeloma activity in patients with relapsed/refractory (R/R) multiple myeloma (MM) harboring t(11;14)
Septiembre 2024

ERIC CLL (Iniciativa de Investigación Europea sobre la LLC)

ERIC CLL (Iniciativa de Investigación Europea sobre la LLC)

Septiembre 2024 (Barcelona, España)
Septiembre 2024

KSMO (Sociedad Coreana de Oncología Médica)

Septiembre 2024

Reunión de la IMS (Sociedad Internacional de Mieloma)

Septiembre 2024

CSCO (Sociedad China de Oncología Clínica)

CSCO (Sociedad China de Oncología Clínica)

Septiembre de 2024 (Xiamen, China)

Resúmenes

A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with CLL/SLL: Preliminary data A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with non-Hodgkin lymphoma (NHL) or Waldenström macroglobulinemia (WM): Preliminary data A phase 2 study of sitravatinib in combination with tislelizumab versus chemotherapy in patients with locally advanced unresectable or metastatic esophageal squamous cell carcinoma that progressed on or after anti–PD-1/anti–PD-L1 antibody therapy CELESTIAL-TNCLL: An ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naive CLL China subgroup results of the phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2-amplified biliary tract cancer (BTC) Combination treatment with novel BCL-2 inhibitor sonrotoclax (BGB-11417) and zanubrutinib induces high rate of complete remission for patients with relapsed/refractory mantle cell lymphoma Efficacy and safety of tislelizumab + chemotherapy vs placebo + chemotherapy in HER2-negative advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: RATIONALE-305 study Chinese subgroup analysis Extended follow-up of ALPINE randomized phase 3 study confirms sustained superior progression-free survival of zanubrutinib versus ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma First interim analysis of a phase 1 study of zanubrutinib plus lenalidomide in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) Impact of first-line treatment with tislelizumab on health-related quality of life in Chinese patients with unresectable hepatocellular carcinoma Improved efficacy and safety of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia in China: a subgroup of ALPINE Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory CLL/SLL: results from the phase 1 BGB-16673-101 study Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results from the phase 1 BGB-16673-101 study Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in patients with relapsed/refractory acute myeloid leukemia Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in treatment-naive patients with acute myeloid leukemia Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax in combination with zanubrutinib for relapsed/refractory CLL/SLL show deep and durable responses Safety and efficacy results of a phase 1 study of the novel BCL2 inhibitor sonrotoclax (BGB-11417) for relapsed/refractory Waldenström macroglobulinemia Sonrotoclax plus dexamethasone is tolerable and demonstrates antimyeloma activity in patients with relapsed/refractory (R/R) multiple myeloma harboring t(11;14) Zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy for patients with advanced HER2-positive breast cancer: Updated results from a Phase Ib/II study Zanubrutinib demonstrates superior progression-free survival (PFS) compared with ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): final analysis of ALPINE randomized phase 3 study Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQOL)
Septiembre 2024

SIE (Sociedad Italiana de Hematología)

SIE (Sociedad Italiana de Hematología)

Septiembre de 2024 (Milán, Italia)

Resúmenes

CELESTIAL-TNCLL: An ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab in treatment-naive CLL Combination of zanubrutinib (zanu) + venetoclax (ven) in patients with treatment-naive (TN) CLL/SLL with del(17p) and/or TP53: Preliminary results from SEQUOIA arm D Combination treatment with sonrotoclax (sonro; BGB-11417) + zanubrutinib (zanu) is well tolerated and achieves deep responses in patients with treatment-naive CLL/SLL: Data from an ongoing phase 1/2 study Intrapatient comparative analysis of zanubrutinib plus obinutuzumab efficacy in relapsed/refractory (R/R) follicular lymphoma (FL) using the growth modulation index (GMI) Monotherapy with second-generation BCL2 inhibitor sonrotoclax (BGB-11417) is well tolerated, with high response rates in relapsed/refractory (R/R) marginal zone lymphoma (MZL): Data from an ongoing phase 1 study Outcomes ≥1 year after transitioning from treatment with ibrutinib (ibru) in the ASPEN study to zanubrutinib (zanu) Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) CLL/SLL: Results from the phase 1 BGB-16673-101 study Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) indolent non-Hodgkin lymphoma (NHL): Results from the phase 1 BGB-16673-101 study Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax (sonro; BGB-11417) in combination with zanubrutinib (zanu) for relapsed/refractory (R/R) CLL/SLL show deep and durable responses Risk of hypertension in patients with CLL/SLL who participated in the ALPINE study: A post hoc analysis
Septiembre 2024

ESMO (Sociedad Europea de Oncología Médica)

ESMO (Sociedad Europea de Oncología Médica)

Septiembre 2024 (Barcelona, España)
Septiembre 2024

WCLC (World Conference on Lung Cancer)

Agosto 2024

Evento anual de APGCS (Cumbre de Gastroenterología Oncológica de Asia-Pacífico)

Julio 2024

PPLC (Pan Pacific Lymphoma Conference)

Junio 2024

ESMO-GI (Congreso sobre Cánceres Gastrointestinales de la Sociedad Europea de Oncología Médica)

Junio 2024

EHA (Asociación Europea de Hematología)

EHA (Asociación Europea de Hematología)

Junio de 2024 (Madrid, España)

Pósteres

Combination treatment with novel BCL-2 inhibitor sonrotoclax (BGB-11417) and zanubrutinib induces high rate of complete remission for patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) Comparative efficacy of Bruton tyrosine kinase inhibitors in the treatment of relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis Efficacy and safety of zanubrutinib vs. venetoclax+ibrutinib in the treatment-naïve (TN) chronic lymphocytic leukemia (CLL): a matching-adjusted indirect comparison (MAIC) Efficacy of zanubrutinib versus acalabrutinib in the treatment of relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC) Indirect comparison of efficacy of zanubrutinib versus acalabrutinib in the treatment of relapsed/refractory mantle cell lymphoma Intrapatient comparative analysis of zanubrutinib plus obinutuzumab efficacy in relapsed/refractory follicular lymphoma using the growth modulation index Matching-adjusted indirect comparison (MAIC) of zanubrutinib versus real-world chemoimmunotherapy (CIT) or chemotherapy (Chemo) in relapsed/refractory marginal zone lymphoma (R/R MZL) Patient-reported outcome (PRO)–based recurrent symptomatic deterioration predicts disease progression: results from the ALPINE trial Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory (R/R) indolent NHL: results from the phase 1 BGB-16673-101 study Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in patients with relapsed/refractory acute myeloid leukemia Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in treatment-naive patients with acute myeloid leukemia Real-world Bruton tyrosine kinase inhibitor treatment patterns and outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in US community oncology practices Real-world adherence and healthcare resource utilization of Bruton tyrosine kinase inhibitors (BTKi) in mantle cell lymphoma Real-world comparative effectiveness of covalent Bruton tyrosine kinase inhibitors (cBTKi) among patients with relapsed/refractory mantle cell lymphoma (R/R MCL) Real-world evaluation of treatment patern, time to next treatment, healthcare resource utilization, and cost of care in follicular lymphoma Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in CLL/SLL Risk of hypertension in patients with CLL/SLL who participated in ALPINE: a post hoc analysis Risk of new-onset hypertension in newly diagnosed chronic lymphocytic leukemia patients treated with Bruton tyrosine kinase inhibitors: a real-world study using the Symphony Health Solutions database Safety and efficacy results of a phase 1 study of the novel BCL2 inhibitor sonrotoclax (BGB-11417) for relapsed/refractory Waldenström's macroglobulinemia Sonrotoclax plus dexamethasone is tolerable and demonstrates antimyeloma activity in patients with relapsed/refractory (R/R) multiple myeloma harboring t(11;14) Zanubrutinib vs other Bruton’s tyrosine kinase inhibitors in relapsed/refractory chronic lymphocytic leukemia: a multilevel network meta-regression

Resúmenes

BGB-11417-203, an ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia CELESTIAL-TNCLL: an ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naive (TN) CLL Combination of zanubrutinib + venetoclax for treatment-naive (TN) CLL/SLL with del(17p) and/or TP53: preliminary results from SEQUOIA arm D Combination treatment with novel BCL-2 inhibitor sonrotoclax (BGB-11417) and zanubrutinib induces high rate of complete remission for patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) Comparative efficacy of Bruton tyrosine kinase inhibitors in the treatment of relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis Efficacy and safety of zanubrutinib vs. venetoclax+ibrutinib in the treatment-naïve (TN) chronic lymphocytic leukemia (CLL): a matching-adjusted indirect comparison (MAIC) Efficacy of zanubrutinib versus acalabrutinib in the treatment of relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC) Indirect comparison of efficacy of zanubrutinib versus acalabrutinib in the treatment of relapsed/refractory mantle cell lymphoma Intrapatient comparative analysis of zanubrutinib plus obinutuzumab efficacy in relapsed/refractory follicular lymphoma using the growth modulation index Matching-adjusted indirect comparison (MAIC) of zanubrutinib versus real-world chemoimmunotherapy (CIT) or chemotherapy (Chemo) in relapsed/refractory marginal zone lymphoma (R/R MZL) Patient-reported outcome (PRO)–based recurrent symptomatic deterioration predicts disease progression: results from the ALPINE trial Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory (R/R) CLL/SLL: Results from the phase 1 BGB-16673-101 study Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed or refractory (R/R) indolent NHL: results from the phase 1 BGB-16673-101 study Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in patients with relapsed/refractory acute myeloid leukemia Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in treatment-naive patients with acute myeloid leukemia Real-world Bruton tyrosine kinase inhibitor treatment patterns and outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in US community oncology practices Real-world adherence and healthcare resource utilization of Bruton tyrosine kinase inhibitors (BTKi) in mantle cell lymphoma Real-world comparative effectiveness of covalent Bruton tyrosine kinase inhibitors (cBTKi) among patients with relapsed/refractory mantle cell lymphoma (R/R MCL) Real-world evaluation of treatment patern, time to next treatment, healthcare resource utilization, and cost of care in follicular lymphoma Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in CLL/SLL Recent patterns of care with btk inhibitors and distribution of social determinants of health among patients with cll/sll in the us community setting Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax (sonro) in combination with zanubrutinib (zanu) for relapsed/refractory (R/R) CLL/SLL show deep and durable responses Risk of hypertension in patients with CLL/SLL who participated in ALPINE: a post hoc analysis Risk of new-onset hypertension in newly diagnosed chronic lymphocytic leukemia patients treated with Bruton tyrosine kinase inhibitors: a real-world study using the Symphony Health Solutions database Safety and efficacy results of a phase 1 study of the novel BCL2 inhibitor sonrotoclax (BGB-11417) for relapsed/refractory Waldenström's macroglobulinemia Sonrotoclax plus dexamethasone is tolerable and demonstrates antimyeloma activity in patients with relapsed/refractory (R/R) multiple myeloma harboring t(11;14) Zanubrutinib vs other Bruton’s tyrosine kinase inhibitors in relapsed/refractory chronic lymphocytic leukemia: a multilevel network meta-regression Zanubrutinib vs. acalabrutinib in B-cell malignancies: an adverse event-based economic analysis
Mayo 2024

ASCO (Sociedad Estadounidense de Oncología Clínica)

ASCO (Sociedad Estadounidense de Oncología Clínica)

Mayo de 2024 (Chicago, Illinois, EE. UU.)

Pósteres

A first in human phase 1a dose escalation study of BGB 15025 (HPK1 inhibitor) as monotherapy and in combination with tislelizumab (TIS; anti PD 1 antibody) in patients (pts) with advanced solid tumors BGB-11417-203, an ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia BGB-A317-212: a multicenter, open-label, phase II study to evaluate the efficacy and safety of tislelizumab in combination with lenvatinib in patients with selected solid tumors CELESTIAL-TNCLL: an ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naïve (TN) CLL Clinical and financial burden of mental health (MH) conditions in patients (pts) with low-grade non-Hodgkin lymphoma (LG-NHL) Comparative efficacy of Bruton tyrosine kinase inhibitors in the treatment of relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis (NMA) Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): minimum 3-year survival follow-up Preoperative (neoadjuvant) therapy with tislelizumab for locally advanced colorectal cancer with high microsatellite instability or deficient mismatch repair: an open-label, single-arm, multicenter phase II study Real-world treatment patterns and outcomes of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic leukemia (CLL/SLL) Tislelizumab first-line (1L) gastric/gastroesophageal junction cancer (G/GEJ) treatment efficacy on patient-reported outcome (PRO)-based symptom endpoints adjusting for informative missing data bias: results from RATIONALE 305

Resúmenes

A first in human phase 1a dose escalation study of BGB-15025 (HPK1 inhibitor) as monotherapy and in combination with tislelizumab (TIS; anti PD 1 antibody) in patients (pts) with advanced solid tumors BGB-11417-203: an ongoing, phase 2 study of sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, in patients with Waldenström macroglobulinemia BGB-A317-212: a multicenter, open-label, phase II study to evaluate the efficacy and safety of tislelizumab in combination with lenvatinib in patients with selected solid tumors CELESTIAL-TNCLL: an ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naïve (TN) CLL Clinical and financial burden of mental health (MH) conditions in patients (pts) with low-grade non-Hodgkin lymphoma (LG-NHL) Comparative efficacy of Bruton tyrosine kinase inhibitors in the treatment of relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis (NMA) Comparison of zanubrutinib (zanu) and acalabrutinib (acala) in B-cell malignancies: an adverse event (AE)-based analysis Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): minimum 3-year survival follow-up Long-term pooled safety analysis of tislelizumab as monotherapy or in combination with chemotherapy in patients with advanced cancers Preoperative (neoadjuvant) therapy with tislelizumab for locally advanced colorectal cancer with high microsatellite instability or deficient mismatch repair: An open-label, single-arm, multicenter phase II study Real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns and outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) in US community oncology practices Real-world adherence and healthcare resource utilization of Bruton tyrosine kinase inhibitors (BTKi) in mantle cell lymphoma Real-world evaluation of treatment pattern, time to next treatment (TTNT), healthcare resource utilization (HCRU), and cost of care in follicular lymphoma (FL) Real-world treatment patterns and outcomes of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic leukemia (CLL/SLL) Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in CLL/SLL Risk of hypertension in patients with CLL/SLL who participated in ALPINE: a post hoc analysis Risk of new-onset hypertension in newly diagnosed chronic lymphocytic leukemia (CLL) patients (pts) treated with Bruton tyrosine kinase inhibitors (BTKis): a real-world data study using the Symphony Health Solutions database Tislelizumab first-line (1L) gastric/gastroesophageal junction cancer (G/GEJ) treatment efficacy on patient-reported outcome (PRO)-based symptom endpoints adjusting for informative missing data bias: results from RATIONALE 305
Mayo 2024

ISPOR (Sociedad Internacional de Farmacoeconomía e Investigación de Resultados)

ISPOR (Sociedad Internacional de Farmacoeconomía e Investigación de Resultados)

Mayo de 2024 (Atlanta, Georgia)
Abril 2024

BSH (Sociedad Británica de Hematología)

BSH (Sociedad Británica de Hematología)

Abril de 2024 (Liverpool, Reino Unido)
Abril 2024

AMCP (Academy of Managed Care Pharmacy)

Abril 2024

ISPE (International Society for Pharmacoepidemiology)

Abril 2024

AACR (Asociación Estadounidense de Investigación en Cáncer)

AACR (Asociación Estadounidense de Investigación en Cáncer)

Abril de 2024 (San Diego, California, EE. UU.)

Pósteres

A first-in-human, phase 1a, dose-escalation study of BGB-10188, a phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor, + tislelizumab (anti-PD-1) in patients with solid tumors BGB-A317-LBL-007-202: a phase 2, randomized, active-controlled, open-label study to evaluate the efficacy and safety of LBL-007 (anti-LAG-3) in combination with tislelizumab (TIS; anti-PD-1) plus chemotherapy (chemo) as first-line (1L) treatment in patients with unresectable locally advanced/metastatic esophageal squamous cell carcinoma (ESCC) BGB-B167, a first-in-class 4-1BB/ CEACAM5 bispecific antibody, exhibits potent in vitro and vivo antitumor activity and superior safety profile in preclinical models BGB-LC-201 (NCT05635708): a phase 2, open-label, multi-arm study of tislelizumab (TIS; anti-PD-1) in combination with investigational agents +/- chemotherapy as first-line treatment for patients with locally advanced, unresectable, or metastatic non–small cell lung cancer (NSCLC) Characterization of the correlation between BTK degradation and tumor growth inhibition of the BTK target protein degraders using PK/PD modeling Exploration of potential biomarkers correlated with efficacy of ociperlimab (anti-TIGIT) plus tislelizumab (anti-PD1) in 1L PD-L1+ non-small cell lung cancer (NSCLC) Liberty-201: maintenance fluoropyrimidine (FP) and bevacizumab with or without anti-lymphocyte activation gene-3 (LAG-3) antibody LBL-007 plus anti-programmed cell death protein-1 (PD-1) antibody tislelizumab (TIS) for patients (pts) with metastatic or unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) colorectal cancer (CRC) Translational assessment of triple combination with tislelizumab (anti-PD-1), LBL-007 (anti-LAG-3) and surzebiclimab (anti-TIM-3) highlights its strong anti-tumor activity and clinical potential in solid tumors such as HNSCC

Resúmenes

A first-in-human, phase 1a, dose-escalation study of BGB-10188, a phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor, + tislelizumab (anti-PD-1) in patients with solid tumors AdvanTIG-204: a phase 2, multicenter, randomized, 3-arm, open-label study investigating the preliminary efficacy and safety of ociperlimab (anti-TIGIT) + tislelizumab (anti-PD-1) + concurrent chemoradiotherapy (cCRT) in patients with untreated limited-stage small cell lung cancer (SCLC) BGB-A317-LBL-007-202: a phase 2, randomized, active-controlled, open-label study to evaluate the efficacy and safety of LBL-007 (anti-LAG-3) in combination with tislelizumab (TIS; anti-PD-1) plus chemotherapy (chemo) as first-line (1L) treatment in patients with unresectable locally advanced/metastatic esophageal squamous cell carcinoma (ESCC) BGB-B167, a first-in-class 4-1BB/ CEACAM5 bispecific antibody, exhibits potent in vitro and vivo antitumor activity and superior safety profile in preclinical models BGB-LC-201 (NCT05635708): a phase 2, open-label, multi-arm study of tislelizumab (TIS; anti-PD-1) in combination with investigational agents +/- chemotherapy as first-line treatment for patients with locally advanced, unresectable, or metastatic non–small cell lung cancer (NSCLC) Characterization of the correlation between BTK degradation and tumor growth inhibition of the BTK target protein degraders using PK/PD modeling Exploration of potential biomarkers correlated with efficacy of ociperlimab (anti-TIGIT) plus tislelizumab (anti-PD1) in 1L PD-L1+ non-small cell lung cancer (NSCLC) Liberty-201: maintenance fluoropyrimidine (FP) and bevacizumab with or without anti-lymphocyte activation gene-3 (LAG-3) antibody LBL-007 plus anti-programmed cell death protein-1 (PD-1) antibody tislelizumab (TIS) for patients (pts) with metastatic or unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) colorectal cancer (CRC) Translational assessment of triple combination with tislelizumab (anti-PD-1), LBL-007 (anti-LAG-3) and surzebiclimab (anti-TIM-3) highlights its strong anti-tumor activity and clinical potential in solid tumors such as HNSCC
Abril 2024

Hematology/Oncology Pharmacy Association (HOPA)

Hematology/Oncology Pharmacy Association (HOPA)

Abril de 2024 (Tampa, Florida, EE. UU.)
Marzo 2024

Conferencia Internacional de la Sociedad Coreana de Hematología y 65.ª reunión anual (ICKSH)

Marzo 2024

44.º Congreso de la Sociedad Francesa de Hematología (SFH)

44.º Congreso de la Sociedad Francesa de Hematología (SFH)

Marzo 2024 (París, Francia)

Resúmenes

Acquired mutations in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) that progressed in the ALPINE study Efficacité similaire de l’ibrutinib dans les essais ALPINE et ELEVATE-RR sur la leucémie lymphoïde chronique en rechute/réfractaire : comparaison indirecte ajustée par appariement Extended follow-up of ALPINE randomized phase 3 study confirms sustained superior progression-free survival of zanubrutinib versus ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL) First results from a phase 1, first-in-human study of the bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory B-cell malignancies Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma (R/R FL) treated with zanubrutinib + obinutuzumab versus obinutuzumab monotherapy: the ROSEWOOD trial Le suivi prolongé de l’étude de phase 3 randomisée ALPINE confirme que le zanubrutinib présente une supériorité à long terme sur le plan de la survie sans progression par rapport à l’ibrutinib dans le traitement de la LLC/LPL R/R Mutations acquises chez des patients atteints de leucémie lymphoïde chronique (LLC) en rechute/réfractaire ayant progressé dans l’étude ALPINE Outcomes ≥1 year after transitioning from treatment with ibrutinib in the ASPEN study to zanubrutinib Premiers résultats d’une étude de phase 1 évaluant le BGB-16673, un dégradeur de la tyrosine kinase de Bruton, chez des patients atteints d’hémopathies lymphoïdes B en rechute/réfractaire Qualité de vie liée (QdV) chez les patients atteints d’un lymphome folliculaire en rechute/réfractaire (LF R/R) traités par zanubrutinib + obinutuzumab par rapport à obinutuzumab en monothérapie : l’essai ROSEWOOD Résultats à ≥ 1 an chez les patients ayant reçu zanubrutinib après un traitement par ibrutinib dans l’étude ASPEN Similar ibrutinib efficacy in ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: matching-adjusted indirect comparison Sonrotoclax (BGB-11417) + zanubrutinib chez des patients présentant une leucémie lymphoide chronique / un lymphome lymphocytique (LLC/LL) non prétraités : essai de phase 1/2 en cours Sonrotoclax (BGB-11417) + zanubrutinib in patients with treatment-naive CLL/SLL: an ongoing phase 1/2 study Tislelizumab, an anti–PD-1 antibody, in patients with relapsed/refractory classical Hodgkin lymphoma in TIRHOL BGB-A317-210: A prospective, multicenter, phase 2 LYSA study conducted in Western countries Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in relapsed/refractory chronic lymphocytic leukemia Toxicité, survie sans progression et qualité de vie des patients traités par zanubrutinib par rapport à ibrutinib dans la leucémie lymphoïde chronique en rechute/réfractaire : analyse Q-TWiST de l’étude ALPINE Zanubrutinib chez des patients intolérants à l’acalabrutinib atteints d’hémopathies lymphoïdes B Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies Évaluation du tislélizumab, anticorps anti-PD-1, chez des patients atteints d’un lymphome de Hodgkin classique en rechute/ réfractaire : étude prospective multicentrique de phase 2 TIRHOL BGB-A317-210 du LYSA
Marzo 2024

ELCC (Congreso Europeo de Cáncer de Pulmón)

Marzo 2024

3.ª Conferencia de Investigación Traslacional de la Escuela Europea de Hematología: Leucemia linfocítica crónica (ESH LLC)

3.ª Conferencia de Investigación Traslacional de la Escuela Europea de Hematología: Leucemia linfocítica crónica (ESH LLC)

Marzo de 2024 (Viena, Austria)
Febrero 2024

Congreso Internacional sobre Neoplasias Hematológicas (ICHM)

Congreso Internacional sobre Neoplasias Hematológicas (ICHM)

Febrero de 2024 (Miami Beach, Florida, EE. UU.)
Febrero 2024

JSMO (Sociedad Japonesa de Oncología Médica)

Febrero 2024

Plenaria virtual de la Sociedad Europea de Oncología Médica (ESMO)

Enero 2024

Congrès de Pneumologie de Langue Française (CPLF)

Enero 2024

Biennale Monégasque de Cancérologie (BMC)

Enero 2024

ASCO-GI (Sociedad Estadounidense de Oncología Clínica - Simposio de Cánceres Gastrointestinales)

ASCO-GI (Sociedad Estadounidense de Oncología Clínica - Simposio de Cánceres Gastrointestinales)

Enero de 2024 (San Francisco, California, EE. UU.)
Diciembre 2023

ASH (Sociedad Estadounidense de Hematología)

ASH (Sociedad Estadounidense de Hematología)

Diciembre de 2023 (San Diego, California, EE. UU.)

Pósteres

Acquired mutations in patients with relapsed/refractory chronic lymphocytic leukemia who progressed in the ALPINE study Broad superiority of zanubrutinib over bendamustine + rituximab across multiple high-risk factors: biomarker subgroup analysis in the phase 3 SEQUOIA study in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma without del(17p) Clinical outcomes in patients with Waldenström macroglobulinemia (WM) receiving ibrutinib on the phase 3 ASPEN study ≥1 year after transitioning to zanubrutinib First results from a phase 1, first-in-human study of Bruton's tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) B-cell malignancies Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma (R/R FL) treated with zanubrutinib+ obinutuzumab versus obinutuzumab monotherapy: the ROSEWOOD trial Monotherapy with second-generation BCL2 inhibitor sonrotoclax (BGB-11417) is well tolerated with high response rates in patients with relapsed/refractory marginal zone lymphoma: data from an ongoing phase 1 study Number needed to treat analyses of zanubrutinib in relapsed/refractory chronic lymphocytic leukemia Real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns among patients with chronic or small lymphocytic leukemia (CLL/SLL) in US community oncology practices Real-world evaluation of treatment discontinuation and healthcare resource utilization in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma Real-world patterns of care and financial burden of patients with follicular lymphoma in the United States Real-world switching pattern, persistence, and associated healthcare resource utilization of Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma in the United States Recent patterns of care with BTK inhibitors and distribution of social determinants of health among patients with CLL/SLL in the US community setting Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison Tislelizumab, an anti-PD1 antibody, in patients with relapsed/refractory classical Hodgkin lymphoma in TIRHOL BGB-A317-210: a prospective multicenter Lysa phase 2 study conducted in Western countries Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in relapsed or refractory chronic lymphocytic leukemia Zanubrutinib in acalabrutinib-intolerant patients (pts) with B-cell malignancies

Resúmenes

A phase 4, observational study evaluating the efficacy and safety of the Bruton tyrosine kinase inhibitor (BTKi) zanubrutinib in patients with Waldenström macroglobulinemia (WM) Acquired mutations in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) that progressed in the ALPINE study Broad superiority of zanubrutinib (zanu) over bendamustine + rituximab (BR) across multiple high-risk factors: Biomarker subgroup analysis in the phase 3 SEQUOIA study in patients with treatment-naive (TN) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without del(17p) Clinical outcomes in patients with Waldenström macroglobulinemia (WM) receiving ibrutinib on the phase 3 ASPEN study ≥1 year after transitioning to zanubrutinib Combination treatment with sonrotoclax (BGB-11417), a second-generation BCL2 inhibitor, and zanubrutinib, a Bruton tyrosine kinase (BTK) inhibitor, is well tolerated and achieves deep responses in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (TN-CLL/SLL): data from an ongoing phase 1/2 study Extended follow-up of ALPINE randomized phase 3 study confirms sustained superior progression-free survival of zanubrutinib versus ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) First results from a phase 1, first-in-human study of Bruton's tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) B-cell malignancies Genomic landscape of ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies treated with zanubrutinib in a phase 2 study Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma (R/R FL) treated with zanubrutinib+ obinutuzumab versus obinutuzumab monotherapy: the ROSEWOOD trial Monotherapy with second-generation BCL2 inhibitor sonrotoclax (BGB-11417) is well tolerated with high response rates in patients with relapsed/refractory marginal zone lymphoma: data from an ongoing phase 1 study Number needed to treat analyses of zanubrutinib in relapsed/refractory chronic lymphocytic leukemia Real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns among patients with chronic or small lymphocytic leukemia (CLL/SLL) in US community oncology practices Real-world evaluation of treatment discontinuation and healthcare resource utilization in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma Real-world patterns of care and financial burden of patients with follicular lymphoma in the United States Real-world switching pattern, persistence, and associated healthcare resource utilization of Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma in the United States Recent patterns of care with BTK inhibitors and distribution of social determinants of health among patients with CLL/SLL in the US community setting Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison Sonrotoclax (BGB-11417) in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma with t(11;14): safety, efficacy, and determination of recommended phase 2 dose Tislelizumab, an anti-PD1 antibody, in patients with relapsed/refractory classical Hodgkin lymphoma in TIRHOL BGB-A317-210: a prospective multicenter Lysa phase 2 study conducted in Western countries Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in relapsed or refractory chronic lymphocytic leukemia Zanubrutinib in acalabrutinib-intolerant patients (pts) with B-cell malignancies Zanubrutinib vs FCR in fit treatment-naive patients with chronic lymphocytic leukemia: a matching-adjusted indirect comparison
Diciembre 2023

ESMO-IO (Inmunooncología de la Sociedad Europea de Oncología Médica)

Noviembre 2023

ESMO-Asia (Sociedad Europea de Oncología Médica - Asia)

ESMO-Asia (Sociedad Europea de Oncología Médica - Asia)

Noviembre 2023 (Singapur)
Noviembre 2023

AGITG (Grupo de Ensayos Gastrointestinales de Australasia)

Noviembre 2023

ISPOR-EU (Sociedad Internacional de Farmacoeconomía e Investigación de Resultados - Europa)

ISPOR-EU (Sociedad Internacional de Farmacoeconomía e Investigación de Resultados - Europa)

Noviembre 2023 (Copenhague, Dinamarca)

Pósteres

Bruton tyrosine kinase inhibitor (BTKi) monotherapy for the treatment of ‘high-risk’ patients with previously untreated chronic lymphocytic leukemia (CLL): a systematic literature review (SLR) Cost-minimization analysis (CMA) of Bruton tyrosine kinase inhibitors (BTKis) in adults with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) Cost-utility analysis (CUA) in chronic lymphocytic leukemia (CLL): Is COVID-19’s impact on national life tables important to consider? Global clinical, economic, health-related quality of life burden, and treatment outcomes in follicular lymphoma: a systematic review Incidence, prevalence, and clinical characteristics of patients with chronic lymphocytic leukemia (CLL) in Spain: natural language processing (NLP) analysis of electronic health records (EHRs) Psychometric validation of QLQ-OES18 in 2L esophageal squamous cell cancer (ESCC) patients treated with tislelizumab versus chemotherapy Q-TWiST analysis is back in the game in oncology clinical trial analysis: a recent trend Quality of life and economic burden of advanced non-small cell lung cancer in medium and small markets (MED&SM): a systematic literature review Targeted treatments for patients with relapsed and/or refractory (R/R) chronic lymphocytic leukemia (CLL): a systematic literature review (SLR) of randomized clinical trials (RCTs) The disease and economic burden of hepatocellular carcinoma in Australia Treatment patterns and adverse events (AEs) in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in France, Italy, and the United Kingdom (UK) Unmet needs and evidence gaps in relapsed/refractory marginal zone lymphoma: findings from a systematic literature review

Resúmenes

Bruton tyrosine kinase inhibitor (BTKi) monotherapy for the treatment of ‘high-risk’ patients with previously untreated chronic lymphocytic leukemia (CLL): a systematic literature review (SLR) Cost-minimization analysis (CMA) of Bruton tyrosine kinase inhibitors (BTKis) in adults with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) Cost-utility analysis (CUA) in chronic lymphocytic leukemia (CLL): Is COVID-19’s impact on national life tables important to consider? Global clinical, economic, health-related quality of life burden, and treatment outcomes in follicular lymphoma: a systematic review Incidence, prevalence, and clinical characteristics of patients with chronic lymphocytic leukemia (CLL) in Spain: natural language processing (NLP) analysis of electronic health records (EHRs) Psychometric validation of QLQ-OES18 in 2L esophageal squamous cell cancer (ESCC) patients treated with tislelizumab versus chemotherapy Q-TWiST analysis is back in the game in oncology clinical trial analysis: a recent trend Quality of life and economic burden of advanced non-small cell lung cancer in medium and small markets (MED&SM): a systematic literature review Targeted treatments for patients with relapsed and/or refractory (R/R) chronic lymphocytic leukemia (CLL): a systematic literature review (SLR) of randomized clinical trials (RCTs) The disease and economic burden of hepatocellular carcinoma in Australia Treatment patterns and adverse events (AEs) in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in France, Italy, and the United Kingdom (UK) Unmet needs and evidence gaps in relapsed/refractory marginal zone lymphoma: findings from a systematic literature review
Noviembre 2023

SPH (Sociedad Portuguesa de Hematología)

Noviembre 2023

Asamblea Científica Anual de BLOOD (BLOOD)

Asamblea Científica Anual de BLOOD (BLOOD)

Noviembre 2023 (Melbourne, Australia)

Resúmenes

A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with CLL/SLL: preliminary data A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with NHL, or Waldenström macroglobulinemia (WM): preliminary data Characterization of the safety/tolerability profile of zanubrutinib and comparison with the profile of ibrutinib in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database Health-related quality of life (HRQOL) in patients with Waldenström macroglobulinemia (WM) treated with zanubrutinib or ibrutinib: results from long-term follow-up of the phase 3 ASPEN trial Incidence, prevalence, and mortality of Waldenström macroglobulinemia (WM) in Australia Incidence, prevalence, and mortality of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in Australia Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA (BGB-3111-214) trial Zanubrutinib demonstrates superior progression-free survival (PFS) vs ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): final analysis of randomized phase 3 ALPINE study Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study Zanubrutinib vs bendamustine + rituximab (BR) in patients with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQOL)
Noviembre 2023

American Society of Nephrology Kidney Week (ASN Kidney Week)

Noviembre 2023

Asamblea Anual de Japan Lung Cancer Society (JLCS)

Octubre 2023

SEHH (Sociedad Española de Hematología y Hemoterapia)

SEHH (Sociedad Española de Hematología y Hemoterapia)

Octubre de 2023 (Sevilla, España)

Resúmenes

Evaluation of treatment and safety patterns in patients with chronic lymphocytic leukemia (CLL) using natural language processing (NLP): perspective of a multicenter observational study in Spain Health-related quality of life in patients (pts) with Waldenström macroglobulinemia (WM) treated with zanubrutinib (zanu) vs ibrutinib (ibr): phase 3 ASPEN trial long-term follow-up results MAHOGANY: phase III trial of zanubrutinib (Z) plus anti-CD20 antibodies against lenalidomide plus rituximab (L+R) in patients (pts.) with relapsed/refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL) (R/R) Phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib for CLL/SLL: preliminary data Phase 1 study with the novel Bcl-2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib for NHL or Waldenström macroglobulinemia (WM): preliminary data Zanubrutinib (ZANU) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study Zanubrutinib (zanu) in relation to ibrutinib (ibr) improves PFS in patients with refractory/recurrent (R/R) CLL: final analysis of the ALPINE study Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)
Octubre 2023

SIE (Sociedad Italiana de Hematología)

SIE (Sociedad Italiana de Hematología)

Octubre de 2023 (Roma, Italia)

Resúmenes

Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL) A phase 1 study with the novel B-cell lymphoma 2 (BCL-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with CLL/SLL: preliminary data A phase 1 study with the novel B-cell lymphoma 2 (BCL-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with non-Hodgkin lymphoma (NHL) or Waldenström macroglobulinemia (WM): preliminary data Health-related quality of life in patients (pts) with Waldenström macroglobulinemia (WM) treated with zanubrutinib (zanu) vs ibrutinib (ibr): results from the phase 3 ASPEN trial long-term follow-up Long-term efficacy and safety of zanubrutinib (zanu) in patients (pts) with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients (pts) with relapsed or refractory (R/R) follicular or marginal zone lymphoma (FL or MZL) Updated safety and efficacy results of zanubrutinib (zanu) in patients with B-cell malignancies who are intolerant of ibrutinib (ibr) and/or acalabrutinib (aca) Zanubrutinib (zanu) demonstrates superior progression-free survival (PFS) vs ibrutinib (ibr) for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): final analysis of phase 3 ALPINE study Zanubrutinib (zanu) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study
Octubre 2023

Sesión de otoño de Florida Society of Clinical Oncology (FLASCO)

Octubre 2023

ESMO (Sociedad Europea de Oncología Médica)

ESMO (Sociedad Europea de Oncología Médica)

Octubre 2023 (Madrid, España)

Resúmenes

AdvanTIG-203: phase 2 randomized, multicenter study of ociperlimab (oci) + tislelizumab (tis) in patients (pts) with unresectable, locally advanced, recurrent/metastatic esophageal squamous cell carcinoma (ESCC) and programmed cell death-ligand 1 (PDL1) positivity AdvanTIG-105: phase 1b dose-expansion study of ociperlimab (oci) + tislelizumab (tis) with chemotherapy (ct) in patients (pts) with metastatic esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) AdvanTIG-202: phase 2 randomized, multicenter, open-label study of tislelizumab (tis) with or without ociperlimab (oci) in patients (pts) with previously treated recurrent/metastatic (r/m) cervical cancer (CC) AdvanTIG-206: phase 2 randomized open-label study of ociperlimab (oci) + tislelizumab (tis) + BAT1706 (bevacizumab biosimilar) Versus tis + BAT1706 in Patients (pts) with advanced hepatocellular carcinoma (HCC) Long-term follow-up of a phase 2 study of tislelizumab (tis) monotherapy in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors Pathological response to neoadjuvant tislelizumab (tis) plus platinum-doublet (PtDb) chemotherapy (CT) in resectable stage II-IIIa NSCLC patients (pts) in the phase 3 (Ph3) RATIONALE-315 trial Phase (Ph) 1/2 study of sitravatinib (sitra) alone or with tislelizumab (tis) in advanced hepatocellular carcinoma (HCC) and gastric/gastroesophageal junction cancer (GC/GEJC) Randomized, global, phase 3 study of tislelizumab (tis) + chemotherapy (chemo) vs placebo (pbo) + chemo as first-line (1l) treatment for advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 Tislelizumab (TIS) plus chemotherapy (chemo) vs placebo (pbo) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): final analysis results of the RATIONALE-305 study Zanidatamab (zani) plus chemotherapy (chemo) and tislelizumab (tis) as first-line (1l) therapy for patients (pts) with advanced HER2-positive (+) gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): updated results from a phase 1b/2 study
Octubre 2023

JSCO (Sociedad Japonesa de Oncología Clínica)

Octubre 2023

DGHO (Sociedades Alemana, Austríaca y Suiza de Hematología y Oncología Médica)

Octubre 2023

JSH (Sociedad Japonesa de Hematología)

Octubre 2023

iwCLL (Taller Internacional sobre LLC)

iwCLL (Taller Internacional sobre LLC)

Octubre de 2023 (Boston, Massachusetts, EE. UU.)
Septiembre 2023

IMS (Sociedad Internacional de Mieloma)

Septiembre 2023

Sociedad Española de Oncología Médica (SEOM)

Septiembre 2023

PTHiT (Sociedad Polaca de Hematología y Medicina Transfusional)

Septiembre 2023

WCLC (World Conference on Lung Cancer)

Septiembre 2023

KSMO (Sociedad Coreana de Oncología Médica)